Senin, 14 April 2014
boards of directors
concentration of power
conflicts of interest
diabetes
Eli Lilly
executive compensation
Medtronic
Novo Nordisk
oligarchy
oligopoly
Sanofi-Aventis
Planned Obsolescence Disguised as Innovation, Oligopoly Disguised as a Free Market, and the Enrichment of Oligarchs
The New York Times published another article in its series on the high cost of US health care. This one, focused on the care of type 1 di...